High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

  title={High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.},
  author={Usama S Gergis and Usama Wissa},
  journal={Current hematologic malignancy reports},
  volume={5 1},
Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. The two hypomethylating agents, 5-azacytidine (azacitidine) and 5-aza-2-deoxycytidine (decitabine), are both effective in high-risk MDS, but about 50% of high-risk MDS patients fail… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
5 Extracted Citations
56 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 56 references

Similar Papers

Loading similar papers…